Benjamin Solomon, MBBS, PhD, discusses the intracranial responses observed in the CROWN trial of lorlatinib versus crizotinib in patients with ALK-positive non–small cell lung cancer.
Benjamin Solomon, MBBS, PhD
Advertisement
Articles by Benjamin Solomon, MBBS, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
2
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
3
Beyond SC Daratumumab: Emerging Therapeutic Approaches for Smoldering Myeloma
4
FDA Approves Liso-Cel as First CAR T for Marginal Zone Lymphoma
5
